Arrowstreet Capital, Limited Partnership Exelixis, Inc. Transaction History

Arrowstreet Capital, Limited Partnership

$136 Billion
Q2 2025

A detailed history of Arrowstreet Capital, Limited Partnership transactions in Exelixis, Inc. stock. As of the latest transaction made, Arrowstreet Capital, Limited Partnership holds 5,262,643 shares of EXEL stock, worth $198 Million. This represents 0.17% of its overall portfolio holdings.

Number of Shares

5,262,643

Previous 3,682,076 42.93%

Holding current value

$198 Million

Previous $136 Million 70.64%

% of portfolio

0.17%

Previous 0.11%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 13, 2025	BUY	$34.13 - $46.26 $53.9 Million - $73.1 Million	1,580,567 Added 42.93%	5,262,643 $232 Million
Q1 2025 May 14, 2025	BUY	$32.38 - $39.16 $16.9 Million - $20.5 Million	522,681 Added 16.54%	3,682,076 $136 Million
Q4 2024 Feb 12, 2025	BUY	$25.39 - $36.46 $41 Million - $58.8 Million	1,613,482 Added 104.37%	3,159,395 $105 Million
Q3 2024 Nov 14, 2024	BUY	$21.96 - $27.6 $7.65 Million - $9.62 Million	348,416 Added 29.1%	1,545,913 $40.1 Million
Q2 2024 Aug 14, 2024	BUY	$20.34 - $23.73 $15.8 Million - $18.4 Million	776,030 Added 184.13%	1,197,497 $26.9 Million
Q1 2024 May 15, 2024	BUY	$20.17 - $23.93 $6.9 Million - $8.18 Million	342,003 Added 430.39%	421,467 $10 Million
Q4 2023 Feb 14, 2024	BUY	$19.25 - $24.13 $1.53 Million - $1.92 Million	79,464 New	79,464 $1.91 Million
Q4 2022 Feb 14, 2023	BUY	$14.96 - $17.39 $2.29 Million - $2.66 Million	152,977 Added 100.9%	304,590 $4.89 Million
Q3 2022 Nov 14, 2022	SELL	$15.68 - $22.27 $12.4 Million - $17.6 Million	-791,142 Reduced 83.92%	151,613 $2.38 Million
Q2 2022 Aug 15, 2022	BUY	$17.44 - $23.16 $16.4 Million - $21.8 Million	942,755 New	942,755 $19.6 Million
Q1 2022 May 13, 2022	SELL	$17.03 - $22.67 $12.5 Million - $16.6 Million	-732,860 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$15.84 - $21.88 $7.61 Million - $10.5 Million	480,418 Added 190.31%	732,860 $13.4 Million
Q3 2021 Nov 12, 2021	BUY	$16.3 - $21.14 $3.69 Million - $4.79 Million	226,637 Added 878.27%	252,442 $5.34 Million
Q2 2021 Aug 13, 2021	BUY	$17.95 - $25.56 $463,199 - $659,575	25,805 New	25,805 $470,000
Q1 2021 May 14, 2021	SELL	$20.53 - $25.22 $14.8 Million - $18.2 Million	-721,933 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$18.39 - $24.8 $12.5 Million - $16.9 Million	681,606 Added 1690.2%	721,933 $14.5 Million
Q3 2020 Nov 12, 2020	SELL	$20.67 - $26.94 $6.99 Million - $9.11 Million	-338,118 Reduced 89.34%	40,327 $986,000
Q2 2020 Aug 12, 2020	BUY	$16.46 - $27.42 $6.23 Million - $10.4 Million	378,445 New	378,445 $8.98 Million
Q1 2020 May 15, 2020	SELL	$14.46 - $21.8 $25.1 Million - $37.9 Million	-1,738,541 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$15.15 - $18.89 $25.1 Million - $31.2 Million	1,654,141 Added 1959.88%	1,738,541 $30.6 Million
Q3 2019 Nov 14, 2019	BUY	$17.68 - $22.65 $1.49 Million - $1.91 Million	84,400 New	84,400 $1.49 Million
Q2 2019 Aug 14, 2019	SELL	$18.93 - $24.75 $842,385 - $1.1 Million	-44,500 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$19.6 - $24.76 $872,200 - $1.1 Million	44,500 New	44,500 $1.06 Million
Q2 2018 Aug 14, 2018	SELL	$18.56 - $22.45 $39.3 Million - $47.6 Million	-2,119,065 Closed	0 $0
Q1 2018 May 14, 2018	BUY	$22.15 - $31.89 $6.11 Million - $8.8 Million	275,936 Added 14.97%	2,119,065 $46.9 Million
Q4 2017 Feb 09, 2018	BUY	$24.23 - $30.93 $11.4 Million - $14.6 Million	471,023 Added 34.33%	1,843,129 $56 Million
Q3 2017 Nov 14, 2017	BUY	$23.35 - $29.24 $32 Million - $40.1 Million	1,372,106	1,372,106 $33.2 Million

Others Institutions Holding EXEL

# of Institutions

688

Shares Held

260M

Call Options Held

1.41M

Put Options Held

1.55M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $12.1B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Arrowstreet Capital, Limited Partnership, based on Form 13F filings with the SEC.

News

Stay updated on Arrowstreet Capital, Limited Partnership with notifications on news.

Account

Arrowstreet Capital, Limited Partnership Exelixis, Inc. Transaction History